BDBM703923 N-[(6-amino-8-methyl-1,5-naphthyridin-3- yl)methyl]-6- (cyclopropylamino)pyrimidine-4- carboxamide. LCMS [M + 1]+ = 350.2. 1H NMR (400 MHz, CDCl3) $#948; ppm 8.67 (d, J = 2.0 Hz, 1 H) 8.36-8.59 (m, 2 H) 7.86 (d, J = 2.0 Hz, 1 H) 7.49 (br s, 1 H) 6.79 (d, J = 0.8 Hz, 1 H) 5.45-5.83 (m, 1 H) 4.86-5.12 (s, 2 H) 4.82 (d, J = 6.0 Hz, 2 H) 2.60-2.71 (m, 4 H) 0.90-1.00 (m, 2 H) 0.61-0.67 (m, 2 H).::US20240368153, Example 7-4
SMILES Cc1cc(N)nc2cc(CNC(=O)c3cc(NC4CC4)ncn3)cnc12
InChI Key
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 5 hits for monomerid = 703923
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent